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Abstract
A previous genome-wide association (GWA) meta-analysis of 12,386 PD cases and 21,026 controls conducted by the
International Parkinson’s Disease Genomics Consortium (IPDGC) discovered or confirmed 11 Parkinson’s disease (PD) loci.
This first analysis of the two-stage IPDGC study focused on the set of loci that passed genome-wide significance in the first
stage GWA scan. However, the second stage genotyping array, the ImmunoChip, included a larger set of 1,920 SNPs
selected on the basis of the GWA analysis. Here, we analyzed this set of 1,920 SNPs, and we identified five additional PD risk
loci (combined p,5610
210, PARK16/1q32, STX1B/16p11, FGF20/8p22, STBD1/4q21, and GPNMB/7p15). Two of these five loci
have been suggested by previous association studies (PARK16/1q32, FGF20/8p22), and this study provides further support
for these findings. Using a dataset of post-mortem brain samples assayed for gene expression (n=399) and methylation
(n=292), we identified methylation and expression changes associated with PD risk variants in PARK16/1q32, GPNMB/7p15,
and STX1B/16p11 loci, hence suggesting potential molecular mechanisms and candidate genes at these risk loci.
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Introduction
Until the recent developments of high throughput genotyping
and genome-wide association (GWA) studies, little was known of
the genetics of typical Parkinson’s disease (PD). Studies of the
genetic basis of familial forms of PD first identified rare highly
penetrant mutations in LRKK2 [1,2], PINK1 [3], SNCA [4], PARK2
[5] and PARK7 [6]. Following these findings, GWA scans for
idiopathic PD identified SNCA and MAPT as unequivocal risk loci
[7,8,9,10,11] as well as implicated BST1 [8], GAK [12], and HLA-
DR [13]. Using sequence based imputation methods [14], the
meta-analysis of several GWA scans [7,9,10,11] conducted by the
International Parkinson’s Disease Genomics Consortium (IPDGC)
identified and replicated five new loci: ACMSD, STK39, MCCC1/
LAMP3, SYT11, and CCDC62/HIP1R [15] and confirmed
association at SNCA, LRRK2, MAPT, BST1, GAK and HLA-DR
[15].
We conducted a two-stage association study. Combining stage 1
and stage 2, the data consist of 12,386 PD cases and 21,026
controls genotyped using a variety of platforms (Table 1). Stage 1
used genome-wide genotyping arrays and our initial analysis [15]
focused on the subset of SNPs that passed genome-wide
significance in stage 1. For stage 2 genotyping, we used a custom
content Illumina iSelect array, the ImmunoChip and additional
PLoS Genetics | www.plosgenetics.org 1 June 2011 | Volume 7 | Issue 6 | e1002142GWAS typing as previously described [15]. The primary content
of the ImmunoChip data focuses on autoimmune disorders but, as
part of a collaborative agreement with the Wellcome Trust Case
Control Consortium 2, we included 1,920 ImmunoChip SNPs on
the basis of the stage 1 GWA PD results.
Here, we report the combined analysis for this full set of 1,920
SNPs. This step1+2 analysis identified seven new loci that passed
genome-wide significance in the meta-analysis. During the process
of analyzing these data and preparing for publication, we became
aware that another group was also preparing a large independent
GWA scan in PD for publication (Do et al, submitted). Following
discussion with this group we agreed to cross validate the top hits
from each study by exchanging summary statistics for this small
number of loci.
To provide further insights into the molecular function of these
associated variants, we tested risk alleles at these loci for
correlation with the expression of physically close gene (expression
quantitative trait locus, eQTL) and the methylation status
(methQTL) of proximal DNA CpG sites in a dataset of 399
control frontal cortex and cerebellar tissue samples extracted post-
mortem from individuals without a history of neurological
disorders.
Results
In addition to eleven loci that passed genome-wide significance
in stage 1 [15], we identified over 100 regions of interest defined as
10 kb windows containing at least one SNP associated at p,10
23.
We submitted the most associated SNP in each region for probe
design and follow-up genotyping using the ImmunoChip platform.
For each region of interest, we also added four SNPs in high level
of linkage disequilibrium (LD) to provide redundancy where the
most associated SNP would not pass the Illumina probe design
step or the assay for that SNP would fail. To complete the array
design we also added all non-synonymous dbSNPs located in
known PD associated regions [1,2,3,4,5,6]. Out of these 2,400
submitted SNPs, 1,920 passed QC and were included in the final
array design. For these 1,920 SNPs we combined stage 1 and stage
2 associated data in a meta-analysis of 12,386 cases and 21,026
controls (Table 1) from the IPDGC. We exchanged summary
statistics for these most significant hits with an additional large,
case-control replication dataset (3,426 PD cases and 29,624
controls) in an attempt to demonstrate independent replication.
On the basis of stage 1+2 results, seven new SNPs passed our
defined genome-wide significance threshold (p,5610
28, Table 2
andFigure1).Theselociareeithernovel orthepreviousevidenceof
association was not entirely convincing in individuals of European
descent. We combined these results with the independent
replication. Five of these seven loci replicated and showed strong
combined evidence of PD association (p,10
210 overall). Taking
eitherthe nearest gene (orthe strongestcandidate when available)to
designate these regions, these five loci are 1q32/PARK16 [7], 4q21/
STBD1, 7p15/GPNMB, 8p22/FGF20 [16] and 16p11/STX1B.
rs708723/1q32 has been previously reported as PD associated
(PARK16, [7,8]) but this SNP lacked the unequivocal evidence of
association in European samples (p=9.47610
210 in stage 2 only).
To understand the potential biological consequences of risk
variation at this locus we tested whether rs708723 was correlated
with either gene expression or DNA methylation status of
proximal transcripts or CpG sites respectively (Table 3). We
found correlations with the expression of NUCKS1 (p=1.8610
27)
and RAB7L1 (p=7.2610
24). We also found correlations with the
methylation state of CpG sites located in the FLJ3269 gene
(p=3.9610
222).
In the case of 16p11/STX1B, the proximal gene to the most
associated SNP rs4889603 is SETD1A. However, STX1B is located
18 kb upstream of rs4889603 and is a more plausible PD
candidate gene [17] owing to its synaptic receptor function. We
therefore used this gene to designate this region. Our methQTL/
eQTL dataset identified a correlation between the rs4889603 risk
allele and increased methylation of a CpG dinucleotide in STX1B
(Table 3).
The SNP rs591323 in the 8p22 region is located ,150 kb
downstream of the FGF20 gene (NCBI build 36.3), for which
association with PD has been suggested previously in familial PD
samples [16,18] but which remained controversial [19]. Our
findings provide further support for a PD association at this locus,
but again, whether the functionally affected transcript is FGF20 or
not remains unclear.
The regions 4q21/STBD1 and 7p15/GPNMD have not been
previously implicated in PD etiology. We found that the risk allele
of rs156429, the most associated SNP in the 7p15 region, is
associated in our eQTL dataset with decreased expression of the
proximal transcript encoded by NUPL2 (Table 3). The same risk
allele is also associated with increased methylation of multiple
CpG sites proximal to GPNMB itself (Table 3). Neither of these
regions contains an obvious candidate gene.
Two additional loci (3q26/NMD3 and 8q21/MMP16) showed
strong evidence of association in stage 1 and 2 but were not disease
associated in the Do et al dataset. Further replication is required to
clarify the role of variation at these loci in risk for PD.
The strongly associated G2019S variant in the LRRK2 gene [20]
was included in the Immunochip design and we replicated the
published association: control frequency: 0.045% case frequency
0.61%, estimated odds ratio: 13.5 with 95% confidence interval:
5.5–43. However, the case collections have been partially screened
for this variant therefore its frequency in cases and the odds ratio is
likely to be underestimated.
The ImmunoChip array design provides some power to detect
whether multiple distinct association signals exist at individual loci.
Indeed, if a SNP showed an independent and sufficiently strong
association in stage 1, it would have been included in stage 2
provided that it was not located in the same 10 kb window as the
primary SNP in the region. There is precedent for this in PD, with
the previous identification of independent risk signals at the SNCA
locus [11]. We therefore used the Immunochip data to test
whether any of the seven loci in Table 2 showed some evidence of
more than one independent signal. None of these seven loci
showed any association (p.0.01) after conditioning on the main
SNP in the region. In contrast, after conditioning on the most
associated SNPs rs356182 in the SNCA region, several SNPs
Author Summary
This paper describes the largest case-control analysis of
Parkinson’s disease to date, with a combined sample set of
over 12,000 cases and 21,000 controls. After combining our
findings with an independent replication dataset of more
than 3,000 cases and 29,000 controls, we found five
additional PD risk loci in addition to the 11 loci previously
identified in earlier consortium efforts. This successful
study further demonstrates the power of the GWA scan
experimental design to find new loci contributing to
disease risk, even in the context of complex disorders like
Parkinson’s disease. These new findings provide insights
into the etiology of PD and will promote a better
understanding of its pathogenesis.
Two-Stage Meta-Analysis of Parkinson’s Disease
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28 for rs2245801
being the most significant).
Lastly, we performed a risk profile analysis to investigate the
power to discriminate cases and controls on the basis of the 16
confirmed common associated variants (Table 4). For each locus,
we estimated the odds ratio on the basis of stage 1 data and we
applied these estimates to compute for each individual in the
ImmunoChip cohort a combined risk score. Solely based on these
16 common variants, and therefore not considering rare highly
penetrant variants such as G2019S in LRKK2 [20], we found that
individuals in the top quintile of the risk score have an estimated
three-fold increase in PD risk compared to individuals in the
bottom quintile (Table 4). We note however that the effect size of
several of these associated variants could be over-estimated (an
effect known as winner’s curse, see [21]) but given the consistent
estimates of odds ratio across studies (Table 4) we expect this bias
to be minimal.
Discussion
The combination of GWA scans and imputation methods in
large cohorts of PD cases and controls has enabled us to identify
five PD associated loci in addition to the 11 previously reported by
us. Two of these loci (1q32/PARK16, 8p22/FGF20) implicate
regions that had been previously associated with PD risk [8,16].
The 1q32/PARK16 showed convincing evidence of association in
the Japanese population [8] but until now the association P-value
had not passed a stringent genome-wide significance threshold in
samples of European descent [7]. The 8p22/FGF20 locus had
been previously reported in a study of familial PD [16] and we
provide the first evidence of association in a case-control study.
The remaining three loci (STX1B/16p11, STBD1/4q21 and
GPNMB/7p15) are new.
Adding the eleven previously reported common variants [15] to
the five convincingly associated loci identified in this study,
common variants at 16 loci have now been associated with PD.
Controlling for the risk score based on the 11 SNPs previously
identified [15] in the risk profile analysis (Table 4), the addition of
these five new loci provides a modest but significant (p=2.2610
23)
improvement of our ability to discriminate PD cases from controls.
Combining eQTL/methylation and case-control data implicates
potential mechanisms which could explain the increased PD risk
associated some of these variants. In particular, the strong eQTL in
the 1q32/PARK16 region with the RAB7L1 and NUCKS1 genes
(Table 3) suggests that either one of these genes could be the biological
effector of this risk locus. However, existing data show that eQTLs are
widespread and this co-localization could be the result of chance alone
[22]. Additional fine-mapping work will be required to assess whether
the expression and case-control data are indeed fully consistent.
While we are unable to unequivocally pinpoint the causative
genes underlying these associations, their known biological function
can suggest likely candidates. At the 1q32/PARK16 loci our
association and eQTL data indicate that RAB7L1 and NUCKS1
are the best candidates. The former is a GTP-binding protein that
plays an important role in the regulation of exocytotic and
endocytotic pathways [23]. Exocytosis is relevant for PD for two
main reasons: firstly, since dopaminergic neurotransmission is
mediated by the vesicular release of dopamine, i.e. dopamine
exocytosis [24], and secondly because it has been shown that alpha-
synuclein knock-out mice develop vesicle abnormalities [25], thus
providing a potential direct link between genetic variability in the
gene and a biological pathway involved in the disease. Less is known
regarding NUCKS1; it has been described to be a nuclear protein,
containing casein kinase II and cyclin-dependant kinases phosphor-
ylation sites and to be highly expressed in the cardiac muscle [26];
but an involvement in PD pathogenesis has yet to be suggested.
At the 16p11/STX1B locus, notwithstanding the fact that other
genes are in the associated region, STX1B is the most plausible
candidate. It has been previously shown to be directly implicated in the
process of calcium-dependent synaptic transmission in rat brain [17],
having been suggested to play a role in the excitatory pathway of
synaptic transmission. Since parkin, encoded by PARK2, negatively
regulates the number and strength of excitatory synapses [27] , it makes
STX1B a very interesting candidate from a biologic perspective.
FGF20 at 8p22 has been suggested to be involved in PD [16],
albeit negative results in smaller cohorts have followed the original
finding [28]. FGF20 is a neurotrophic factor that exerts strong
neurotrophic properties within brain tissue, and regulates central
nervous development and function [29]. It is preferentially
expressed in the substantia nigra [30], and it has been reported
to be involved in dopaminergic neurons survival [30].
The ImmunoChip data provide limited resolution for the
detection of multiple independent association signals in these
regions. A previous study [31] reported some evidence of allelic
heterogeneity at the 1q32/PARK16 locus but the ImmunoChip data
do not support this result. A previous study [11] also reported two
independent associations at the 4q22/SNCA locus and our data are
consistentwiththisscenario.However,thenewlyreportedsecondary
association (rs2245801) is in low LD (r
2=0.21) with rs2301134, the
SNP reportedin[11]as an independent association. Takentogether,
these findings suggest that at least three independent associations
exist at SNCA/4q22. A more exhaustive fine-mapping analysis using
either sequencing of large cohorts or targeted genotyping arrays will
also be required to fully explore this locus.
As yet, we do not know which of the variants and which genes
within each region are exerting the pathogenic effect. We cannot
exclude that some of the currently reported variants are in fact
tagging high penetrance, but rare, mutations [32]. Nevertheless, the
successfulidentificationofthese 16riskloci further demonstrates the
powerofthe GWAstudydesign,eveninthe context ofdisorderslike
Table 1. Sample size and genotyping platform for the
cohorts included in stage 1 (top set of rows), stage 2 (middle
set of rows), and independent replication (bottom row).
Cohort Controls Cases Genotyping platform
United Kingdom 5,200 1,705 Illumina 660W-Quad
USA-NIA 3,034 971 Illumina HumanHap 550
USA-dbGAP 857 876 Illumina 370 K
German 944 742 Illumina HumanHap550
French 1,984 1039 Illumina 610-Quad
Total Stage 1 12,019 5,333
Icelandic 1,427 479 Illumina HumanHap 300
Dutch 2,024 772 Illumina 610-Quad
USA 2,215 2,807 ImmunoChip
United Kingdom 1,864 1,271 ImmunoChip
Dutch 402 304 ImmunoChip
French 363 267 ImmunoChip
German 712 1,153 ImmunoChip
Total Stage 2 9,007 7,053
Stage 1+Stage 2 21,026 12,386
Do et al- USA 29,624 3,426
doi:10.1371/journal.pgen.1002142.t001
Two-Stage Meta-Analysis of Parkinson’s Disease
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that furtherand larger association analyses,perhaps usingdedicated
high-throughput genotyping arrays like the ImmunoChip, will
continue to yield new insights into PD etiology.
Material and Methods
Genotyping and case control cohorts
Participating studies were either genotyped using the ImmunoChip
as part of a collaborative agreement with the ImmunoChip
Consortium, or as part of previous GWA studies provided by
members of the IPDGC or freely available from dbGaP [7,9,10,11].
Genotyping of the UK cases using the Immunochip was undertaken
by the WTCCC2 at the Wellcome Trust Sanger Institute which also
genotyped the UK control samples. The constituent studies
comprising the IPDGC have been described in detail elsewhere
[15], although a summary of individual study quality control is
available as part of Table S1. In brief all studies followed relatively
uniform quality control procedures such as: minimum call rate per
sample of 95%, mandatory concordance between self-reported and
X-chromosome-heterogeneity estimated sex, exclusion of SNPs with
greater than 5% missingness, Hardy Weinberg equilibrium p-values at
am i n i m u mo f1 0
27, minor allele frequencies at a minimum of 1%,
exclusion of first degree relatives, and the exclusion of ancestry outliers
based on either principal components or multidimensional scaling
analyses using either PLINK [33] or EIGENSTRAT [34] to remove
non-European ancestry samples. All GWAS studies utilized in this
analysis(and in the QTLanalyses) were imputed using MACHv1.0.16
[14] to conduct a two-stage imputation based on the August 2009
haplotypes from initial low coverage sequencing of 112 European
ancestry samples in the 1000 Genomes Project [35], filtering the data
for a minimum imputation quality of (RSQR.0.3) [14]. Logistic
regression models were utilized to quantify associations with PD
incorporating allele dosages as the primary predictor of disease.
Imputed data was analyzed using MACH2DAT, and genotyped
SNPs were analyzed using PLINK. All models were adjusted for
covariates of components 1 and 2 from either principal components or
multidimensional scaling analyses to account for population substruc-
ture and stochastic genotypic variation (except in the UK-GWAS data
which were not adjusted for population substructure).
Association test statistics
Single SNP test statistics were combined across datasets using a
score test methodology, essentially assuming equal odds ratio
across cohorts. In addition, fixed and random effects meta-
analyses were implemented in R (version 2.11) to confirm that the
score test approximation does not affect the interpretation of the
results. We also tested the relevant SNPs heterogeneity across
cohorts and no significant heterogeneity was detected (Table S2).
Data exchange
We communicated to our colleagues in charge of the
independent study (Do et al) the seven SNPs listed in Table 2.
For this subset of SNPs they selected the marker with the highest r
2
value on their genotyping platform and provided us with the
following summary statistics: odds ratio, direction of effect,
standard error for the estimated odds ratio and one degree-of-
freedom trend test P-value.
eQTL analysis and methylation analysis
Quantitative trait analyses were conducted to infer effects of risk
SNPs on proximal CpG methylation and gene expression. For the
five replicated SNP associations (Table 2), all available CpG probes
and expression probes within +/21 MB of the target SNP were
Figure 1. Forest plots detailing effect estimates from the combined analysis of all data contributed by the International Parkinson
Disease Genomics Consortium (joint estimates describing constituent effects of Stage 1+Stage 2).
doi:10.1371/journal.pgen.1002142.g001
Table 2. Summary statistics for the seven SNPs that pass genome-wide significance (p,5610
28) in the combined stage 1+2
analysis and that have either not been reported in published PD association studies.
Stage 1 Stage 2 Stage 1+2 Do et al Combined
SNP Chrom Gene(s) Alleles MAF OR (95%CI) P OR (95%CI) PP
OR
(95%CI) PP
rs708723 1q32 RAB7L1/PARK16 T.C 0.439 0.905
(0.862–0.95)
6.68610
25 0.863
(0.824–0.905)
9.47610
210 1.00610
212 0.758
(0.65–0.88)
2.12610
26 8.82610
215
rs34016896 3q26 NMD3 C.T 0.305 1.14
(1.09–1.2)
3.00610
27 1.08
(1.02–1.14)
0.00399 1.81610
28 1.002
(0.95–1.06)
0.954 1.31610
26
rs6812193 4q21 STBD1 C.T 0.36 0.886
(0.843–0.932)
2.52610
26 0.906
(0.864–0.95)
5.29610
25 7.46610
210 0.839
(0.79–0.89)
7.55610
210 1.17610
217
rs156429 7p15 GPNMB A.G 0.403 0.894
(0.849–0.942)
2.15610
25 0.893
(0.852–0.937)
3.86610
26 3.27610
210 0.901
(0.85–0.95)
0.000193 3.05610
213
rs591323 8p22 FGF20 G.A 0.271 0.884
(0.836–0.935)
1.59610
25 0.875
(0.83–0.923)
8.49E610
27 7.45610
211 0.932
(0.88–0.99)
0.023 1.92610
211
chr8:894421578q21 MMP16 C.T 0.0247 1.38
(1.21–1.57)
1.10610
26 1.29
(1.12–1.49)
0.000451 2.26610
29 0.969
(0.86–1.09)
0.589 2.36610
25
rs4889603 16p11 STX1B A.G 0.413 1.12
(1.06–1.18)
4.13610
25 1.15
(1.1–1.21)
8.21610
29 2.66610
212 1.070
(1.01–1.13)
0.014 6.98610
213
1q32/PARK16 has been reported previously but is included because these data provide for the first time unequivocal evidence of association. P-values are computed
using a one-degree-of-freedom regression trend test, including two principal components as covariates and combining the results across cohorts using a score test
methodology. P-values are two-tailed and odds ratios are reported for the minor alleles. The notation X.Y indicates that X is the major allele and Y the minor allele.
Allele frequencies were estimated using the UK control data. OR: odds ratio.
doi:10.1371/journal.pgen.1002142.t002
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cerebellar tissue samples. 399 samples were assayed for genome-wide
gene expression on Illumina HumanHT-12 v3 Expression Beadchips
and 292 samples were assayed using Infinium HumanMethylation27
Beadchips, both per manufacturer’s protocolsin each brain region. A
more in depth description of the sample series comprising the QTL
analyses, relevant laboratory procedures and quality requirements
may be found in [15]. The QTL analysis utilized multivariate linear
regression models to estimate effects of allele dosages per SNP on
expression and methylation levels adjusted for covariates of age at
death, gender, the first 2 component vectors from multi-dimensional
scaling, post mortem interval (PMI), brain bank from where the
Table 3. Significant eQTL associations (p,0.01) between the five SNPs with positive replication data (Table 2) and proximal (cis)
changes in gene expression/methylation in frontal cortex and cerebellar tissue.
Assay Region SNP Region
Gene
Tagged by
Probe Illumina Probe Alleles
Effect
Estimate
Standard
Error
Unadjusted
P
False
Discovery
Rate
Adjusted P
Expression Frontal Cortex rs156429 7p15/GPNMB NUPL2 ILMN_1789616 A.G 0.083 0.018 3.6E-06 1.0E-04
rs156429 7p15/GPNMB NUPL2 ILMN_2115154 A.G 0.078 0.017 3.1E-06 1.0E-04
rs708723 1q32/PARK16 NUCKS1 ILMN_1680692 T.C 0.155 0.03 1.8E-07 1.5E-05
rs708723 1q32/PARK16 RAB7L1 ILMN_1813685 T.C 20.062 0.018 7.2E-04 1.2E-02
rs4889603 16p11/STX1B ZNF668 ILMN_1739236 A.G 0.062 0.015 4.1E-05 8.7E-04
rs4889603 16p11/STX1B MYST1 ILMN_1804679 A.G 20.053 0.018 3.4E-03 4.8E-02
Cerebellum rs156429 7p15/GPNMB NUPL2 ILMN_1789616 A.G 0.133 0.025 1.0E-07 3.7E-06
rs156429 7p15/GPNMB NUPL2 ILMN_2115154 A.G 0.131 0.023 1.2E-08 1.0E-06
rs708723 1q32/PARK16 NUCKS1 ILMN_1680692 T.C 0.13 0.029 5.3E-06 1.1E-04
rs708723 1q32/PARK16 RAB7L1 ILMN_1813685 T.C 20.106 0.02 1.3E-07 3.7E-06
rs4889603 16p11/STX1B ZNF668 ILMN_1739236 A.G 0.075 0.02 1.3E-04 2.3E-03
rs4889603 16p11/STX1B BCL7C ILMN_2371147 A.G 0.066 0.022 2.6E-03 3.8E-02
Methylation Frontal Cortex rs156429 7p15/GPNMB GPNMB cg17274742 A.G 20.027 0.005 5.1E-07 3.2E-05
rs156429 7p15/GPNMB GPNMB cg22932819 A.G 20.009 0.002 1.6E-07 1.3E-05
rs6812193 4q21/STBD1 GENX-3414 cg17010112 C.T 0.008 0.002 9.4E-04 3.0E-02
rs708723 1q32/PARK16 FLJ32569 cg14159672 T.C 20.219 0.022 3.1E-24 3.9E-22
rs708723 1q32/PARK16 FLJ32569 cg14893161 T.C 20.176 0.017 3.9E-25 9.6E-23
rs4889603 16p11/STX1B BCL7C cg07896225 A.G 20.002 0.001 9.7E-04 3.0E-02
rs4889603 16p11/STX1B STX1B cg25033993 A.G 0.012 0.003 8.2E-05 3.4E-03
Cerebellum rs156429 7p15/GPNMB GPNMB cg17274742 A.G 20.015 0.003 2.1E-06 1.3E-04
rs708723 1q32/PARK16 FLJ32569 cg14159672 T.C 20.246 0.023 3.0E-27 3.7E-25
rs708723 1q32/PARK16 FLJ32569 cg14893161 T.C 20.202 0.018 2.6E-28 6.4E-26
doi:10.1371/journal.pgen.1002142.t003
Table 4. Estimated PD risk profile for the five cohorts genotyped using the Immunochip.
1
st quintile 2
nd quintile 3
rd quintile 4
th quintile 5
th quintile
Study Trend P-value AUC OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
USA ,2E-16 0.614 1 – 1.54 1.29–1.84 1.92 1.61–2.29 2.21 1.85–2.65 3.03 2.52–3.64
UK ,2e-16 0.636 1 – 1.34 1.05–1.71 1.79 1.41–2.28 2.35 1.86–2.99 3.11 2.46–3.96
Germany 1.29E-11 0.692 1 – 1.32 0.98–1.79 1.88 1.38–2.58 1.88 1.38–2.56 2.57 1.88–3.53
France 5.19E-13 0.675 1 – 1.69 0.99–2.92 1.13 0.65–1.98 3.30 1.95–5.67 5.92 3.42–10.52
Netherlands 5.08E-05 0.601 1 – 1.06 0.65–1.74 1.35 0.83–2.20 1.91 1.18–3.11 2.36 1.45–3.86
Combined ,2E-16 0.645 1 – 1.43 1.26–1.61 1.79 1.58–2.02 2.22 1.96–2.50 3.02 2.67–3.42
% Cases per Quintile 37.90 46.06 51.15 56.56 63.75
Risk scores for the 16 confirmed loci were computed using the odds ratio estimated from the genome-wide case-control genotype data. Individuals were split into
quintile on the basis of their risk scores. The odds ratios quantify the effect of the computed risk quintile on the probability of being a PD case (one-degree-of-freedom
logistic trend test with the PD status as a binary outcome variable and the quintiles, coded as 1–5, as covariates). The first quantile group was taken as a reference
group. OR: odds ratio, CI: confidence interval.
doi:10.1371/journal.pgen.1002142.t004
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batch the samples were processed. A total of 670 candidate QTL
associations were tested: 87 expression QTLs in the cerebellum
samples, 85 expression QTLs in the frontal cortex samples, 249
methylation QTLs in the cerebellum samples and 249 methylation
QTLs in the frontal cortex samples. Multiple test correction was
undertaken using false discovery rate adjusted p-values,0.05 to
dictate significance, with the p-value adjustment undertaken in each
series separately, stratified by brain region and assay. A complete list
of all QTL associations tested is included in Table S3.
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